FigureĀ 4.
(A) The number of EBNA2 sequencing reads from immunoprecipitated Mutu III and GM12878 DNA are plotted per million background-subtracted total reads and aligned with the human genome at CD79A. The black arrow indicates the direction of gene transcription. GM12878 EBF-1 and H3K27 acetylation ChIP-seq data from ENCODE are also shown at the bottom of the panel. RBP-J binding sites identified by ChIP-seq [9] using the IB4 LCL are shown as their called MACS peaks (black bars) and summits of peaks (lines). (B) Transcription factor binding motifs at the upstream promoter-proximal peak at CD79A showing overlapping EBF-1 and potential RBP-J motifs. (C) EBF-1 and potential RBP-J overlapping motifs at the CD79A proximal promoter peak. (D) EBNA2 binding at CD79B. (E) Transcription factor binding motifs at the CD79B binding site.
EBNA2 binding sites at CD79A and CD79B.

(A) The number of EBNA2 sequencing reads from immunoprecipitated Mutu III and GM12878 DNA are plotted per million background-subtracted total reads and aligned with the human genome at CD79A. The black arrow indicates the direction of gene transcription. GM12878 EBF-1 and H3K27 acetylation ChIP-seq data from ENCODE are also shown at the bottom of the panel. RBP-J binding sites identified by ChIP-seq [9] using the IB4 LCL are shown as their called MACS peaks (black bars) and summits of peaks (lines). (B) Transcription factor binding motifs at the upstream promoter-proximal peak at CD79A showing overlapping EBF-1 and potential RBP-J motifs. (C) EBF-1 and potential RBP-J overlapping motifs at the CD79A proximal promoter peak. (D) EBNA2 binding at CD79B. (E) Transcription factor binding motifs at the CD79B binding site.

Close Modal

or Create an Account

Close Modal
Close Modal